LitAlert ~~

    • Retinoblastoma protein expression and its predictors in triple-negative breast cancer.
    • Patel JM, Goss A, Garber JE, Torous V, Richardson ET, Haviland MJ, Hacker MR, Freeman GJ, Nalven T, Alexander B, Lee L, Collins LC, Schnitt SJ, Nadine Tung N.
    • NPJ Breast Cancer. 2020 Jun 5;6:19. doi: 10.1038/s41523-020-0160-4. eCollection 2020.
    • Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations.
    • Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B.
    • Breast J. 2020 Jun 4. doi: 10.1111/tbj.13922. Epub ahead of print.
    • PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 4.
    • Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    • Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
    • BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.
    • Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    • Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T.
    • Breast Cancer Res Treat. 2020 Jun 3. doi: 10.1007/s10549-020-05716-0. Epub ahead of print.
    • Association of gBRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study.
    • Yoshihara K, Enomoto T, Aoki D, Watanabe Y, Kigawa J, Takeshima N, Inomata H, Hattori K, Jinushi M, Tsuda H, Sugiyama T.
    • Cancer Sci. 2020 Jun 3. doi: 10.1111/cas.14513. Epub ahead of print.
    • Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    • Alter BP, Best AF.
    • Breast Cancer Res Treat. 2020 Jun 2. doi: 10.1007/s10549-020-05710-6. Epub ahead of print.
    • Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
    • Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, McGoldrick K, Garber JE, Savage SA, Khincha PP, Gareth Evans D, Achatz MI, Nichols KE, Maxwell K, Schiffman JD, Sandoval R; Li-Fraumeni Exploration (LIFE) Consortium, James PA, Spurdle AB.
    • Hum Mutat. 2020 Jun 2. doi: 10.1002/humu.24060. Epub ahead of print.
    • Identifying Patients With Pancreatic Cancer Likely to Respond.
    • Harrison P.
    • Medscape. 2020 Jun 2.

    Original research:

    Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

    • CHMP Issues Positive Opinion for Lynparza as Maintenance Treatment in BRCA-Mutated Pancreatic Cancer.
    • [No author given]
    • Precision Oncology News. 2020 Jun 1.
    • Intraoperative radiotherapy in early breast cancer: observational comparison with whole breast radiotherapy.
    • Oliver Guillén JR, Hernando Almudi E, Molina Osorio G, Ibañez Carreras R, Font Gómez JA, Vicente Gómez I, García Mur C, Casamayor Franco MC.
    • Cir Esp. 2020 May 31:S0009-739X(20)30161-5. English, Spanish. doi: 10.1016/j.ciresp.2020.04.024.
    • Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
    • Hirotsu Y, Schmidt-Edelkraut U, Nakagomi H, Sakamoto I, Hartenfeller M, Narang R, Soldatos TG, Kaduthanam S, Wang X, Hettich S, Brock S, Jackson DB, Omata M.
    • Int J Mol Sci. 2020 May 29;21(11):E3895. doi: 10.3390/ijms21113895.
    • Identifying Lynch Syndrome–Related Breast Cancers.
    • Sorscher S.
    • JCO Precis Oncol. 2020;4:579. doi: 10.1200/PO.20.00085. Epub 2020 May 27.


    Lynch Syndrome and Breast Cancer Risk: Weighing the Data.

    Original research:

    No Evidence of Increased Risk of Breast Cancer in Women With Lynch Syndrome Identified by Multigene Panel Testing.

    • Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
    • Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI.
    • Cancer Treat Rev. 2020 May 26;87:102040. doi: 10.1016/j.ctrv.2020.102040. Epub ahead of print.
    • Review
    • The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations.
    • Jeyakumar A, Chua T, Lam AK, Gopalan V.
    • Crit Rev Oncol Hematol. 2020 May 22;152:102989. doi: 10.1016/j.critrevonc.2020.102989. Epub ahead of print.
    • Review
    • Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
    • Knisely AT, Stewart ME, Garcia C, Thomas MH, Modesitt SC, Ring KL.
    • Gynecol Oncol Rep. 2020 May 22;33:100587. doi: 10.1016/j.gore.2020.100587.
    • Germline variants and phenotypic spectrum in a Canadian cohort of individuals with diffuse gastric cancer.
    • Aronson M, Swallow C, Govindarajan A, Semotiuk K, Cohen Z, Kaurah P, Velsher L, Ambus I, Buckley K, Forster-Gibson C, Meschino WS, Blumenthal A, Kim RH, Brar S.
    • Curr Oncol. 2020 Apr;27(2):e182-e190. doi: 10.3747/co.27.5663. Epub 2020 May 1.
    • Characteristics of early-onset pancreatic cancer and its association with familial pancreatic cancer and hereditary pancreatic cancer syndromes.
    • Eguchi H, Kobayashi S, Gotoh K, Noda T, Doki Y.
    • Ann Gastroenterol Surg. 2020 Mar 27;4(3):229-233. doi: 10.1002/ags3.12326.